gefitinib and dihydrotestosterone
gefitinib has been researched along with dihydrotestosterone in 2 studies
Compound Research Comparison
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (dihydrotestosterone) | Trials (dihydrotestosterone) | Recent Studies (post-2010) (dihydrotestosterone) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 9,325 | 307 | 1,517 |
Protein Interaction Comparison
Protein | Taxonomy | gefitinib (IC50) | dihydrotestosterone (IC50) |
---|---|---|---|
Plasma kallikrein | Homo sapiens (human) | 0.0031 | |
Glucocorticoid receptor | Homo sapiens (human) | 0.54 | |
Sex hormone-binding globulin | Homo sapiens (human) | 0.0038 | |
Progesterone receptor | Oryctolagus cuniculus (rabbit) | 0.44 | |
Progesterone receptor | Homo sapiens (human) | 7.3 | |
Mineralocorticoid receptor | Homo sapiens (human) | 0.36 | |
Sex hormone-binding globulin | Rattus norvegicus (Norway rat) | 0.023 | |
Androgen receptor | Homo sapiens (human) | 0.0048 | |
Androgen receptor | Rattus norvegicus (Norway rat) | 0.4041 | |
Androgen receptor | Mus musculus (house mouse) | 0.001 | |
Mineralocorticoid receptor | Rattus norvegicus (Norway rat) | 2.1 | |
Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) | 0.0026 |
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C | 1 |
Earp, HS; Gregory, CW; Liu, Y; Majumder, S; McCall, W; Mohler, JL; Sartor, CI; Whang, YE | 1 |
Other Studies
2 other study(ies) available for gefitinib and dihydrotestosterone
Article | Year |
---|---|
Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Dihydrotestosterone; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; Nitriles; Prostatic Neoplasms; Quinazolines; Tosyl Compounds; Transplantation, Heterologous | 2005 |
Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Topics: Acetylation; Androgen Receptor Antagonists; Androgens; Cell Line, Tumor; Chromatin; Chromatin Immunoprecipitation; Dihydrotestosterone; ErbB Receptors; Gefitinib; Histones; Humans; Immunoglobulin Fragments; Lapatinib; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Response Elements; Transcription, Genetic | 2005 |